Charles Geyer named associate group chair of NRG Oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The NRG Oncology Group Chairs created the position of associate group chair and selected Charles E. Geyer to fill the position, effective immediately. He will serve alongside the three NRG Oncology group chairs, Quynh-Thu Le, Robert Mannel, and Norman Wolmark.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Two years of adjuvant Verzenio (abemaciclib) plus endocrine therapy reduced the risk of death by 15.8% versus ET alone and resulted in sustained long-term improvements in invasive disease-free survival and distant relapse-free survival, in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer, according to the primary overall survival analysis of the phase III monarchE trial.
Positive high-level results showed Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival versus trastuzumab emtansine in patients with HER2-positive early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment and a high-risk of disease recurrence, according to a planned interim analysis of the DESTINY-Breast05 phase III trial. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login